Kiniksa Pharmaceuticals International, plc Quarterly Debt-to-equity in % from Q1 2019 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Kiniksa Pharmaceuticals International, plc quarterly Debt-to-equity history and growth rate from Q1 2019 to Q3 2024.
  • Kiniksa Pharmaceuticals International, plc Debt-to-equity for the quarter ending September 30, 2024 was 23 %, a 38.1% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 23 +6.35 +38.1% Sep 30, 2024
Q2 2024 21.1 +4.33 +25.9% Jun 30, 2024
Q1 2024 19.3 +0.48 +2.55% Mar 31, 2024
Q4 2023 17.7 -6.08 -25.6% Dec 31, 2023
Q3 2023 16.7 -11 -39.7% Sep 30, 2023
Q2 2023 16.8 -12.2 -42.2% Jun 30, 2023
Q1 2023 18.8 -5.47 -22.5% Mar 31, 2023
Q4 2022 23.8 +4.93 +26.2% Dec 31, 2022
Q3 2022 27.6 +12.1 +78% Sep 30, 2022
Q2 2022 29 +16.5 +132% Jun 30, 2022
Q1 2022 24.3 +13.8 +132% Mar 31, 2022
Q4 2021 18.8 +9.53 +103% Dec 31, 2021
Q3 2021 15.5 +6.26 +67.6% Sep 30, 2021
Q2 2021 12.5 +1.77 +16.5% Jun 30, 2021
Q1 2021 10.5 -1.23 -10.5% Mar 31, 2021
Q4 2020 9.3 -3.13 -25.2% Dec 31, 2020
Q3 2020 9.26 -3.79 -29.1% Sep 30, 2020
Q2 2020 10.7 -1.42 -11.7% Jun 30, 2020
Q1 2020 11.7 +0.97 +9.03% Mar 31, 2020
Q4 2019 12.4 Dec 31, 2019
Q3 2019 13 Sep 30, 2019
Q2 2019 12.2 Jun 30, 2019
Q1 2019 10.7 Mar 31, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.